link
Bookmarks
RECIST 1.1
Brett W. Carter, MD
To access 4,300 diagnoses written by the world's leading experts in radiology, please log in or subscribe.Log inSubscribe

KEY FACTS

  • Terminology

    • Imaging Anatomy

      • Evaluation of Response

        TERMINOLOGY

        • Abbreviations

          • Response evaluation criteria in solid tumors (RECIST)
        • Definitions

          • Revised response criteria published in 2009
          • Updated previous RECIST criteria
        • Rationale and Key Concepts

          • Patient eligibility
            • Patients with measurable disease at baseline
              • Measurable disease: Indicates presence of at least 1 measurable lesion
            • Enrolled in protocols where objective tumor response is primary endpoint
          • Assess disease at baseline
            • Evaluate for measurable disease
            • Identify target and nontarget lesions
            • Measure target lesions
            • Tumor burden: Sum of target lesions
          • Assess disease at follow-up
            • Measure target lesions
            • Assess nontarget lesions
            • Identify new lesions
            • Calculate time point response
        • Significant Differences Between RECIST & RECIST 1.1

          • Change in definition of
            • Tumor burden
            • Measurement of lymph nodes
            • Definition of progressive disease
            • Nonmeasurable progressive disease
            • Confirmation of response
            • New lesions

        IMAGING ANATOMY

        • Measurable and Nonmeasurable Disease

          • Imaging Protocols

            • Baseline Evaluation

              Evaluation of Response

              • Key Concepts

                • Target Lesion Evaluation

                  • New Lesions

                    • Overall Response

                      • FDG PET & PET/CT

                        • Missing Assessments and Nonevaluable Designation

                          • Lesion Recurrence

                            • Confirmation of Response

                              Selected References

                              1. Litière S et al: The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. Eur J Cancer. 50(10):1847-53, 2014
                              2. Nishino M et al: Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 195(2):281-9, 2010
                              3. van Persijn van Meerten EL et al: RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 20(6):1456-67, 2010
                              4. Eisenhauer EA et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45(2):228-47, 2009
                              5. Eisenhauer EA et al: Response assessment in solid tumours (RECIST) and supporting papers (version 1.1). Eur J. Cancer. 45(2):225-310, 2009
                              Related Anatomy
                              Loading...
                              Related Differential Diagnoses
                              Loading...
                              References
                              Tables

                              Tables

                              KEY FACTS

                              • Terminology

                                • Imaging Anatomy

                                  • Evaluation of Response

                                    TERMINOLOGY

                                    • Abbreviations

                                      • Response evaluation criteria in solid tumors (RECIST)
                                    • Definitions

                                      • Revised response criteria published in 2009
                                      • Updated previous RECIST criteria
                                    • Rationale and Key Concepts

                                      • Patient eligibility
                                        • Patients with measurable disease at baseline
                                          • Measurable disease: Indicates presence of at least 1 measurable lesion
                                        • Enrolled in protocols where objective tumor response is primary endpoint
                                      • Assess disease at baseline
                                        • Evaluate for measurable disease
                                        • Identify target and nontarget lesions
                                        • Measure target lesions
                                        • Tumor burden: Sum of target lesions
                                      • Assess disease at follow-up
                                        • Measure target lesions
                                        • Assess nontarget lesions
                                        • Identify new lesions
                                        • Calculate time point response
                                    • Significant Differences Between RECIST & RECIST 1.1

                                      • Change in definition of
                                        • Tumor burden
                                        • Measurement of lymph nodes
                                        • Definition of progressive disease
                                        • Nonmeasurable progressive disease
                                        • Confirmation of response
                                        • New lesions

                                    IMAGING ANATOMY

                                    • Measurable and Nonmeasurable Disease

                                      • Imaging Protocols

                                        • Baseline Evaluation

                                          Evaluation of Response

                                          • Key Concepts

                                            • Target Lesion Evaluation

                                              • New Lesions

                                                • Overall Response

                                                  • FDG PET & PET/CT

                                                    • Missing Assessments and Nonevaluable Designation

                                                      • Lesion Recurrence

                                                        • Confirmation of Response

                                                          Selected References

                                                          1. Litière S et al: The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. Eur J Cancer. 50(10):1847-53, 2014
                                                          2. Nishino M et al: Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 195(2):281-9, 2010
                                                          3. van Persijn van Meerten EL et al: RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 20(6):1456-67, 2010
                                                          4. Eisenhauer EA et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45(2):228-47, 2009
                                                          5. Eisenhauer EA et al: Response assessment in solid tumours (RECIST) and supporting papers (version 1.1). Eur J. Cancer. 45(2):225-310, 2009